KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.

Tarun Saluja, Ganesh Kumar Rai, Shipra Chaudhary, Piush Kanodia, Bishnu Rath Giri, Deok Ryun Kim, Jae Seung Yang, Il-Yeon Park, Seung-Eun Kyung, Sridhar Vemula, Jagadeesh Reddy E, Bomi Kim, Birendra Prasad Gupta, Sue Kyoung Jo, Ji Hwa Ryu, Ho Keun Park, Jong Hoon Shin, Yoonyeong Lee, Hun Kim, Jerome H Kim, Zenaida Reynoso Mojares, T Anh Wartel, Sushant Sahastrabuddhe

Vaccine 40(40) 5828-5834

PMID36064672
PMCID-
DOI10.1016/j.vaccine.2022.08.034
发表日期2022-09-05
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Typhoid fever is a common disease in developing countries especially in the Indian subcontinent and Africa. The available typhoid conjugate vaccines (TCV) have been found to be highly immunogenic in infants and children less than 2 years of age. Many countries are planning to adopt TCV in their routine EPI programs around 9 months of age when measles containing vaccines are given. Therefore, Vi-DT TCV was tested in 9-15 months aged healthy infants in Nepal to demonstrate non-interference with a measles containing vaccine. METHODS: This was a randomized, open label, phase III study to assess the immune non-interference, safety, and reactogenicity of Vi-DT typhoid conjugate vaccine when given concomitantly with measles, mumps and rubella (MMR) vaccine. A total of 360 participants aged 9-15 months were enrolled and randomized equally into Vi-DT + MMR (180 participants) or MMR alone (180 participants) group and were evaluated for immunogenicity and safety 28 days post vaccination. RESULTS: Using the immunogenicity set, difference between proportions (95% CI) of the Vi-DT + MMR group vs MMR alone group were -2.73% (-8.85, 3.38), -3.19% (-11.25, 4.88) and 2.91% (-3.36, 9.18) for sero-positivity rate of anti-measles, anti-mumps and anti- rubella, respectively. Only the lower bound of the range in difference of the proportions for sero-positivity rate of anti-mumps did not satisfy the non-inferiority criteria as it was above the -10% limit, which may not be of clinical significance. These results were confirmed in the per protocol set. There were no safety concerns reported from the study and both Vi-DT + MMR and MMR alone groups were comparable in terms of solicited and unsolicited adverse events . CONCLUSIONS: Results indicated that there is non-interference of MMR vaccine with Vi-DT and Vi-DT conjugate vaccine could be considered as an addition to the EPI schedule among children at risk of contracting typhoid.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。